Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medicago CoVLP COVID-19 Vaccine Phase 1
NCT04450004Phase 1Completed
- Sponsor
- Medicago Inc.
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Covifenz in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by Medicago Inc. Primary endpoints: Immediate adverse events at 30 months, Solicited local and systemic adverse events at 7 days and 6 more. Started Jul 2020; status: completed.
02
Drugs
Covifenz
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04450004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04450004.